• DongKoo Bio & Pharma corrected its business suspension disclosure following a court decision granting an injunction to stay enforcement.
• The stay pauses the cancellation of its GMP compliance certification for solid oral dosage manufacturing until 30 days after the main ruling.
• The company stated the decision means no impact on business operations during the suspension period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DongKoo Bio & Pharma Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008000294), on October 08, 2026, and is solely responsible for the information contained therein.